The Effect of Gliatamin (Chonline Alphoscerate) on Depressive Mood in Type 2 Diabetes Patients

Launched by YONSEI UNIVERSITY · Feb 16, 2017

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a medication called Gliatamin (choline alphoscerate) on improving depressive moods in patients with type 2 diabetes. Researchers believe that by helping to reduce feelings of depression, the medication might also enhance the overall quality of life and better manage blood sugar levels in these patients. The study is currently recruiting participants, and anyone aged 50 and older with type 2 diabetes and certain levels of depression may be eligible to join.

To participate, individuals must have their diabetes under control and meet specific criteria related to their mental health. Participants will be asked to understand the study process and will need to give written consent to join. Throughout the trial, participants can expect close monitoring and support as they explore the potential benefits of this treatment. It's important to note that certain health conditions or current treatments may prevent some people from being eligible, so discussing personal health history with the study team is crucial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Type 2 diabetic patients
• • Age ≥ 50
• • Glycemic control: HbA1c ≤ 10.0%
• • 10 ≤ Beck Depression Inventory (BDI) \<30 points
• • Participants who can undergo contraception in case of being in childbearing period
• • Understands the study procedure, alternatives, and risks and voluntarily agrees to participate by giving written informed concent
• Exclusion Criteria:
• • Type 1 diabetes, Secondary diabetes, gestational diabetes
• • Ongoing dementia treatment or anti-depressive disorder medication
• • Uncontrolled psychiatric disorder
• • BDI ≥ 30 points
• • Heavy alcoholics
• • Underlying chronic liver disease (hemochromatosis, liver cell carcinoma, autoimmune liver disease, liver cirrhosis, chronic viral hepatitis)
• • Allergy or hypersensitivity to target medication or any of its components
• • Renal failure, moderate or severe renal impairment (estimated glomerular filtration rate \< 30 mL/min/1.73 m2), or ongoing dialysis
• • Abnormal liver function (AST/ALT \> x3 upper normal limit)
• • History of alcohol or drug abuse in the previous 3 months
• • Premenopausal women who are nursing or pregnant
• • Human immunodeficiency virus (HIV) or human immunodeficiency virus (AIDS)
• • chronic pancreatitis or pancreatic cancer